Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04970212 · ClinicalTrials.gov registry record
Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
A clinical trial of Carcinoma, Hepatocellular and Metastatic Liver Cancer, sponsored by Techsomed Medical Technologies.
- Completed
- Registry status
- 65
- Enrollment target
- 6
- Study locations
NCT04970212: Completed study of Carcinoma, Hepatocellular and Metastatic Liver Cancer, sponsored by Techsomed Medical Technologies.
NCT04970212 is a study of Carcinoma, Hepatocellular and Metastatic Liver Cancer that has completed, run by Techsomed Medical Technologies. The registered enrollment target is 65 participants, below the 610-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (89% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04970212, a study of Carcinoma, Hepatocellular and Metastatic Liver Cancer, has completed, sponsored by Techsomed Medical Technologies.
- COMPLETED
- Registry status
- 65 participants
- Enrollment target
- 6
- Study locations
Study Summary
Clinical study planned to demonstrate that the BioTraceIO Lite, available post-procedure, is effective at estimating the area of tissue damage as measured on 24-hour post-procedure (T=24hrs) CECT scan and that it is safe, based on an assessment of device-related Adverse Events. Multi-center (up to 6 investigational sites) prospective single-arm clinical investigation 50 evaluable subjects total stratified by cancer type (primary hepatocellular carcinoma vs. secondary liver metastases).
Primary Outcome
Incidence and severity of device-related adverse events (including serious adverse events (SAE)) occurring between the beginning of the liver tissue ablation procedure and the completion of the T=24hrs contrast-enhanced computed tomography (CECT) scan. There is no comparator for this endpoint.
Conditions Studied
Interventions
- DEVICE BioTraceIO Lite
Study Locations (6)
Arizona
- Mayo Clinic - Phoenix
California
- Stanford Medicine - Stanford
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
Ohio
- University Hospitals Cleveland - Cleveland
Texas
- Houston Methodist Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2021-09-24 |
| Est. Completion | 2022-10-08 |
What the finished NCT04970212 record still lists
NCT04970212 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 610-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Carcinoma, Hepatocellular appearing as the primary indexed condition, and to 1 intervention - of which BioTraceIO Lite is the first listed.
NCT04970212 lists 6 locations in 6 states (Arizona, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT04970212 about?
NCT04970212 is a clinical study titled "Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures". Clinical study planned to demonstrate that the BioTraceIO Lite, available post-procedure, is effective at estimating the area of tissue damage as measured on 24-hour post-procedure (T=24hrs) CECT scan and that it is safe, based on an assessment of device-related Adverse Events. Multi-center (up to ...
What is the current status of trial NCT04970212?
This trial is currently completed. The enrollment target is 65 participants. The study started on 2021-09-24. Estimated completion is 2022-10-08.
What conditions does trial NCT04970212 study?
This clinical trial studies the following conditions: Carcinoma, Hepatocellular, Metastatic Liver Cancer.
What interventions are being tested in trial NCT04970212?
The interventions under investigation include: BioTraceIO Lite (DEVICE).
Who is sponsoring clinical trial NCT04970212?
This trial is sponsored by Techsomed Medical Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04970212 being conducted?
This trial has 6 study locations across Arizona, California, Massachusetts, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Hepatocellular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04970212's enrollment target sits among peer trials
65 17th of 27 higher than 11 of 27 other Carcinoma, Hepatocellular trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Hepatocellular trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia
RECRUITING · NA
-
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
RECRUITING
-
National Liver Cancer Screening Trial
RECRUITING · Phase 4
-
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
RECRUITING · NA
-
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
RECRUITING · Phase 1
-
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI